Taipei, Taiwan – Sinovac said the COVID-19 vaccine is safe in children aged 3 to 17 years, based on preliminary data, and he presented the data to Chinese drug regulators.
More than 70 million shots of Sinovac’s vaccine have been given worldwide, including in China.
China has approved its use in adults, but it has not yet been used in children because their immune system may respond differently to the vaccine.
ASTRAZENECA INCLUDED POSSIBLE INFORMATION FROM COVID-19 TEST, SIA NIAID
Gang Zeng, Sinovac’s medical director, said at a news conference that clinical trials with more than 550 subjects earlier and in the middle of the stage showed that the vaccine would elicit an immune response.
March 15, 2021: Sinovac said the COVID-19 vaccine is safe for children ages 3 to 17, based on preliminary data, and he submitted the data to Chinese drug regulators for approval.
(Chinatopix Via AP)
Two recipients developed high fever in response to the vaccine, one a 3-year-old and the other a 6-year-old. The rest of the subjects experienced mild symptoms, Zeng said.
UK CORONAVIRUS VARIANT CAN CAUSE HEART ISSUES IN PETS
“It is very welcome to demonstrate that the vaccine is safe and could potentially elicit a beneficial immune response against SARS-CoV-2,” said Eng Eong Ooi, a professor at Duke NUS Medical School in Singapore. development of a separate leader is said. Covid19 vaccine. However, he said the data the company had publicly provided was not enough to provide a conclusive response to the findings.
Children are much less likely to be seriously ill with COVID-19, but they are still at risk and can spread the virus. And although vaccination campaigns worldwide are targeted at adults, children need to be vaccinated to end the pandemic.
CLICK HERE FOR FULL CORONAVIRUS COVERAGE
The Pfizer vaccine is cleaned for use from the age of 16 and is being studied at the age of 12-16. Moderna is studying the vaccine in children aged 12 and older and last week announced a new study testing its use in children under 12.
The state-owned Sinopharm, which has two COVID-19 vaccines, is also investigating the efficacy of the vaccines in children. The company said in January it had submitted clinical data to regulators, although it was unclear whether it was for one or both vaccines.